InnoCAR-T consists of a balanced mix of academic and industrial partners brought together to address the challenge of enhancing the therapeutic impact of CAR-T-based therapies for cancer patients. Our network hinges on integrating new academic immunotherapeutic concepts with intersectoral expertise in manufacturing and gene regulation.
This dual involvement of academia and industry is integral to the successful execution of the programme and the development of new and optimally-formulated cancer immunotherapeutics. The academic beneficiaries are already at the forefront of point-of-care (POC) CAR-T production, bispecific antibody-derivative development and nanotechnology, whereas the industrial beneficiaries have all requisite state-of-the-art and proprietary technologies for gene regulation and manufacturing innovations.
Applying such an array of cutting-edge technologies and linking experts working on various aspects of antibody/CAR engineering and tumor immunity, InnoCAR-T establishes an integrated, interdisciplinary and innovative research environment to nurture and bring forth Doctoral Candidates who will be ideally placed to address global challenges in health and well-being.